Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

Tongji University

Status and phase

Withdrawn

Phase 2

Conditions

Long COVID-19

Treatments

Biological: UC-MSCs

Study type

Interventional

Funder types

Other

Identifiers

DFSC-2023(CR)-02

Details and patient eligibility

About

To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The age ranges from 18 to 85 (inclusive), regardless of gender.
Patients with Confirmed SARS-CoV-2 infection, according to the consensus of the Chinese diagnostic criteria for COVID-19 (Tentative tenth Edition).
Patients with symptoms of long COVID-19 3 months from the onset of COVID-19, lasting for at least 2 months, and the symptoms cannot be explained by other diseases.
Be expected to live longer than 1 year.
Volunteer to participate in this clinical study and sign the written informed consent.

Exclusion criteria

Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation.
T lymphocyte abnormality, HIV positive.
Highly allergic or have a history of severe allergy.
Pregnant and lactating women.
Patients with severe autoimmune disease history;
Patients with uncontrolled chronic diseases or serious complications;
Patients with malignant tumors;
Patients with pulmonary embolism, acute coronary syndrome, cerebral embolism or at high risk of thromboembolism;
Patients with severe organ dysfunction
Other situations that the researchers think are not suitable for participating in this study